Media contact: Tesia Williams media-relations@its.jnj.com Investor contact: Jessica Moore investor-relations@its.jnj.com For immediate release Johnson & Johnson Reports Q3 2023 Results • 2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%* • Earnings per share (EPS) of $1.69 increasing 4.3% and adjusted EPS of $2.66 increasing by 19.3%* • Company is increasing 2023 full-year guidance midpoints for sales 5 and adjusted EPS New Brunswick, N.J. (October 17, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2023. “Johnson & Johnson delivered strong results and significant pipeline advances in the third quarter, providing a solid foundation for future sustained growth,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow.” Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of Johnson & Johnson. The Company recognized a one-time, non-cash gain of approximately $21 billion in the quarter as part of discontinued operations related to the final separation of its Consumer Health business. Overall Financial Results Q3 ($ in millions, except EPS) 2023 2022 % Change Reported Sales $21,351 $19,996 6.8% Net Earnings $4,309 $4,310 0.0% EPS (diluted) $1.69 $1.62 4.3% Q3 Non-GAAP* ($ in Millions, except EPS) 2023 2022 % Change Operational Sales 1,2 6.4% Adjusted Operational Sales 1,3 4.9% Adjusted Net Earnings 1,4 $6,777 $5,938 14.1% Adjusted EPS (diluted) 1,4 $2.66 $2.23 19.3% 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Note: Values may have been rounded -- 1 of 21 -- Regional Sales Results Q3 % Change ($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $11,996 $10,794 11.1% 11.1 - 8.9 International 9,355 9,202 1.6 0.7 0.9 0.3 Worldwide $21,351 $19,996 6.8% 6.4 0.4 4.9 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: Values may have been rounded Segment Sales Results Q3 % Change ($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted Operational1,3 Innovative Medicine $13,893 $13,214 5.1% 4.3 0.8 4.4 MedTech 7,458 6,782 10.0 10.4 (0.4) 6.0 Worldwide $21,351 $19,996 6.8% 6.4 0.4 4.9 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: The Innovative Medicine segment was previously referred to as the Pharmaceutical segment Values may have been rounded Third Quarter 2023 Segment Commentary: Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency. Innovative Medicine Innovative Medicine worldwide adjusted operational sales grew 4.4%*. Excluding the COVID-19 Vaccine, operational sales grew 8.2%*. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), Other Oncology, and CARVYKTI (ciltacabtagene autoleucel) in Oncology, STELARA (ustekinumab), TREMFYA (guselkumab), and SIMPONI/SIMPONI ARIA (golimumab) in Immunology, SPRAVATO (esketamine) in Neuroscience, and UPTRAVI (selexipag) in Pulmonary Hypertension. Growth was partially offset by COVID-19 Vaccine (Ad26.COV2.S) in Infectious Diseases, ZYTIGA (abiraterone acetate) and IMBRUVICA (ibrutinib) in Oncology, and REMICADE (infliximab) in Immunology. MedTech MedTech worldwide adjusted operational sales grew 6.0%*, driven primarily by electrophysiology products in Interventional Solutions, wound closure products in General Surgery, contact lenses in Vision, and biosurgery in Advanced Surgery. MedTech worldwide operational sales grew 10.4%*, with the acquisition of Abiomed contributing 4.6%. -- 2 of 21 -- Notable New Announcements in the Quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com. Regulatory Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy Press Release U.S. FDA Approves TALVEY (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma Press Release European Commission Approves TALVEY (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma Press Release European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI (teclistamab) Press Release Janssen Submits Application to the European Medicines Agency for RYBREVANT (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations 1 Press Release Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations Press Release Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations Press Release U.S. FDA Approves AKEEGA (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer Press Release Data Release Janssen to Highlight Latest Research from Nipocalimab Clinical Development Program to Address Unmet Need in Myasthenia Gravis at AANEM 2023 Meeting 1 Press Release Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO1 Press Release TREMFYA (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study 1 Press Release Janssen Highlights Latest Research for TREMFYA (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress 1 Press Release Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Press Release Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT (amivantamab-vmjw) Plus Chemotherapy with and without Lazertinib versus Chemotherapy Alone in Patients with EGFR-Mutated Non- Small Cell Lung Cancer after Disease Progression on Osimertinib Press Release Treatment with RYBREVANT (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer Press Release Janssen to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2023 Annual Meeting1 Press Release Product Launch Biosense Webster Launches the OPTRELL Mapping Catheter with TRUEref Technology for Mapping of Complex Cardiac Arrhythmias Press Release Other Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc. Press Release Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation Press Release Johnson & Johnson Marks New Era as Global Healthcare Company with Updated Visual Identity Press Release 1 Subsequent to the quarter -- 3 of 21 -- Full-Year 2023 Guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) October 2023 August 2023 Adjusted Operational Sales 1,2,5 Change vs. Prior Year / Mid-point 7.2% – 7.7% / 7.5% 6.2% – 7.2% / 6.7% Operational Sales 2,5/ Mid-point Change vs. Prior Year / Mid-point $84.4B – $84.8B / $84.6B 8.5% – 9.0% / 8.7% $83.6B – $84.4B / $84.0B 7.5% – 8.5% / 8.0% Estimated Reported Sales 3,5/ Mid-point Change vs. Prior Year / Mid-point $83.6B – $84.0B / $83.8B 7.5% – 8.0% / 7.7% $83.2B – $84.0B / $83.6B 7.0% – 8.0% / 7.5% Adjusted Operational EPS (Diluted) 2,4 / Mid-point Change vs. Prior Year / Mid-point $10.02 – $10.08 / $10.05 12.2% – 12.8% / 12.5% $9.90 – $10.00 / $9.95 11.0% – 12.0% / 11.5% Adjusted EPS (Diluted) 3,4 / Mid-point Change vs. Prior Year / Mid-point $10.07 – $10.13 / $10.10 12.7% – 13.3% / 13.0% $10.00 – $10.10 / $10.05 12.0% – 13.0% / 12.5% Average Shares Outstanding (Diluted) 6 ~2,557.2 ~2,557.2 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: October 2023 = $1.08 and July 2023 = $1.09 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine 6 Full Year 2023 Projected Average Shares Outstanding (Diluted) only reflects impact from the Kenvue exchange offer Note: Percentages may have been rounded Other modeling considerations will be provided on the webcast. Webcast Information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. -- 4 of 21 -- Non-GAAP Financial Measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to Investors Concerning Forward-Looking Statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to realize the anticipated benefits from the separation of the Company’s Consumer Health business; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward- looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. -- 5 of 21 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Sales to customers by segment of business Innovative Medicine (1,2) U.S. 8,249 7,438 10.9 10.9 - 23,090 21,229 8.8 8.8 - International 5,644 5,776 (2.3) (4.3) 2.0 17,947 18,171 (1.2) 0.8 (2.0) 13,893 13,214 5.1 4.3 0.8 41,037 39,400 4.2 5.1 (0.9) Innovative Medicine excluding COVID-19 Vaccine (1,2) U.S. 8,249 7,438 10.9 10.9 - 23,090 21,109 9.4 9.4 - International 5,603 5,287 5.9 4.3 1.6 16,874 16,801 0.4 2.7 (2.3) 13,852 12,725 8.9 8.2 0.7 39,964 37,910 5.4 6.4 (1.0) MedTech U.S. 3,747 3,356 11.6 11.6 - 11,345 9,932 14.2 14.2 - International 3,711 3,426 8.3 9.2 (0.9) 11,382 10,719 6.2 10.0 (3.8) 7,458 6,782 10.0 10.4 (0.4) 22,727 20,651 10.0 12.0 (2.0) U.S. 11,996 10,794 11.1 11.1 - 34,435 31,161 10.5 10.5 - International 9,355 9,202 1.6 0.7 0.9 29,329 28,890 1.5 4.2 (2.7) Worldwide 21,351 19,996 6.8 6.4 0.4 63,764 60,051 6.2 7.5 (1.3) U.S. 11,996 10,794 11.1 11.1 - 34,435 31,041 10.9 10.9 - International 9,314 8,713 6.9 6.3 0.6 28,256 27,520 2.7 5.5 (2.8) Worldwide excluding COVID-19 Vaccine (1) 21,310 $ 19,507 9.2 % 9.0 0.2 62,691 $ 58,561 7.1 % 8.4 (1.3) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales reconciliation schedule (2) Previously referred to as Pharmaceutical THIRD QUARTER NINE MONTHS Percent Change -- 6 of 21 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. 11,996 $ 10,794 11.1 % 11.1 - 34,435 $ 31,161 10.5 % 10.5 - Europe 4,727 4,844 (2.4) (7.8) 5.4 15,448 15,540 (0.6) (1.0) 0.4 Western Hemisphere excluding U.S. 1,171 1,059 10.5 12.8 (2.3) 3,383 3,084 9.7 15.0 (5.3) Asia-Pacific, Africa 3,457 3,299 4.8 9.4 (4.6) 10,498 10,266 2.2 8.7 (6.5) International 9,355 9,202 1.6 0.7 0.9 29,329 28,890 1.5 4.2 (2.7) Worldwide 21,351 $ 19,996 6.8 % 6.4 0.4 63,764 $ 60,051 6.2 % 7.5 (1.3) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. THIRD QUARTER NINE MONTHS Percent Change -- 7 of 21 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 21,351 $ 100.0 19,996 $ 100.0 6.8 Cost of products sold 6,606 30.9 6,172 30.9 7.0 Gross Profit 14,745 69.1 13,824 69.1 6.7 Selling, marketing and administrative expenses 5,400 25.3 4,975 24.9 8.5 Research and development expense 3,447 16.2 3,485 17.4 (1.1) In-process research and development impairments 206 1.0 - - Interest (income) expense, net (182) (0.8) (99) (0.5) Other (income) expense, net 499 2.3 226 1.1 Restructuring 158 0.7 65 0.3 Earnings before provision for taxes on income 5,217 24.4 5,172 25.9 0.9 Provision for taxes on income 908 4.2 862 4.3 5.3 Net earnings from Continuing Operations 4,309 $ 20.2 4,310 $ 21.6 0.0 Net earnings from Discontinued Operations, net of tax 21,719 148 Net earnings 26,028 $ 4,458 $ Net earnings per share (Diluted) from Continuing Operations 1.69 $ 1.62 $ 4.3 Net earnings per share (Diluted) from Discontinued Operations 8.52 $ 0.06 $ Average shares outstanding (Diluted) 2,549.7 2,661.3 Effective tax rate from Continuing Operations 17.4 % 16.7 % Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from Continuing Operations 8,033 $ 37.6 7,060 $ 35.3 13.8 Net earnings from Continuing Operations 6,777 $ 31.7 5,938 $ 29.7 14.1 Net earnings per share (Diluted) from Continuing Operations 2.66 $ 2.23 $ 19.3 Effective tax rate from Continuing Operations 15.6 % 15.9 % (1) See Reconciliation of Non-GAAP Financial Measures. THIRD QUARTER 2023 2022 -- 8 of 21 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 63,764 $ 100.0 60,051 $ 100.0 6.2 Cost of products sold 19,755 31.0 18,512 30.8 6.7 Gross Profit 44,009 69.0 41,539 69.2 5.9 Selling, marketing and administrative expenses 15,702 24.6 14,907 24.8 5.3 Research and development expense 10,605 16.6 10,425 17.4 1.7 In-process research and development impairments 255 0.4 610 1.0 Interest (income) expense, net (277) (0.4) (137) (0.2) Other (income) expense, net 7,055 11.1 15 0.0 Restructuring 433 0.6 200 0.4 Earnings before provision for taxes on income 10,236 16.1 15,519 25.8 (34.0) Provision for taxes on income 1,042 1.7 2,376 3.9 (56.1) Net earnings from Continuing Operations 9,194 $ 14.4 13,143 $ 21.9 (30.0) Net earnings from Discontinued Operations, net of tax 21,910 1,278 Net earnings 31,104 $ 14,421 $ Net earnings per share (Diluted) from Continuing Operations 3.53 $ 4.93 $ (28.4) Net earnings per share (Diluted) from Discontinued Operations 8.42 $ 0.48 $ Average shares outstanding (Diluted) 2,603.4 2,667.5 Effective tax rate from Continuing Operations 10.2 % 15.3 % Adjusted earnings from continuing operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from Continuing Operations 23,574 $ 37.0 21,491 $ 35.8 9.7 Net earnings from Continuing Operations 19,847 $ 31.1 18,364 $ 30.6 8.1 Net earnings per share (Diluted) from Continuing Operations 7.62 $ 6.89 $ 10.6 Effective tax rate from Continuing Operations 15.8 % 14.6 % (1) See Reconciliation of Non-GAAP Financial Measures. NINE MONTHS 2023 2022 -- 9 of 21 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2023 2022 2023 2022 Net Earnings from Continuing Operations, after tax- as reported $4,309 $4,310 $9,194 $13,143 Pre-tax Adjustments Litigation related (51) 219 6,986 604 Intangible Asset Amortization expense 1,132 958 3,384 2,967 COVID-19 Vaccine related costs 1 44 377 653 653 Restructuring related 2 384 92 659 253 Medical Device Regulation 3 74 78 223 208 Acquisition, integration and divestiture related 22 - 102 - (Gains)/losses on securities 1,005 164 1,076 684 IPR&D impairments 206 - 255 610 Other - - - (7) Tax Adjustments Tax impact on special item adjustments 4 (482) (312) (2,769) (900) Tax legislation and other tax related 134 52 84 149 Adjusted Net Earnings from Continuing Operations, after tax $6,777 $5,938 $19,847 $18,364 Average shares outstanding (Diluted) 2,549.7 2,661.3 2,603.4 2,667.5 Adjusted net earnings per share from Continuing Operations (Diluted) $2.66 $2.23 $7.62 $6.89 Operational adjusted net earnings per share from Continuing Operations (Diluted) $2.54 $7.60 Notes: 1 2 3 4 European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Third Quarter Nine Months Ended In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $149 million in the quarter ($424 million Q3 YTD) include the termination of partnered and non-partnered program costs and asset impairments. In the third quarter of 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense in the quarter of $235 million primarily includes inventory and instrument reserves related to the market and product exits. COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments. -- 10 of 21 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 5.1% 10.0% 6.8% U.S. 10.9% 11.6% 11.1% International (2.3)% 8.3% 1.6% WW Currency 0.8 (0.4) 0.4 U.S. - - - International 2.0 (0.9) 0.9 WW Operational 4.3% 10.4% 6.4% U.S. 10.9% 11.6% 11.1% International (4.3)% 9.2% 0.7% Abiomed (4.6) (1.6) U.S. (7.6) (2.3) International (1.7) (0.6) All Other Acquisitions and Divestitures 0.1 0.2 0.1 U.S. 0.0 0.3 0.1 International 0.2 0.1 0.2 WW Adjusted Operational 4.4% 6.0% 4.9% U.S. 10.9% 4.3% 8.9% International (4.1)% 7.6% 0.3% Adjusted Operational Sales Growth THIRD QUARTER 2023 ACTUAL vs. 2022 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 11 of 21 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 4.2% 10.0% 6.2% U.S. 8.8% 14.2% 10.5% International (1.2)% 6.2% 1.5% WW Currency (0.9) (2.0) (1.3) U.S. - - - International (2.0) (3.8) (2.7) WW Operational 5.1% 12.0% 7.5% U.S. 8.8% 14.2% 10.5% International 0.8% 10.0% 4.2% Abiomed (4.7) (1.6) U.S. (7.9) (2.5) International (1.6) (0.6) All Other Acquisitions and Divestitures 0.1 0.1 0.1 U.S. 0.0 0.1 0.0 International 0.2 0.0 0.1 WW Adjusted Operational 5.2% 7.4% 6.0% U.S. 8.8% 6.4% 8.0% International 1.0% 8.4% 3.7% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth NINE MONTHS 2023 ACTUAL vs. 2022 ACTUAL Segments -- 12 of 21 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER INNOVATIVE MEDICINE SEGMENT (2,3,4) 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency IMMUNOLOGY US 3,193 $ 2,876 11.0% 11.0% - 8,506 $ 8,230 3.3% 3.3% - Intl 1,656 1,411 17.4% 15.2% 2.2% 4,951 4,587 7.9% 10.3% -2.4% WW 4,849 4,287 13.1% 12.4% 0.7% 13,457 12,817 5.0% 5.9% -0.9% REMICADE US 296 350 -15.4% -15.4% - 849 1,099 -22.7% -22.7% - US Exports (5) 38 39 -2.5% -2.5% - 112 163 -31.3% -31.3% - Intl 127 169 -25.1% -24.3% -0.8% 449 606 -25.9% -23.0% -2.9% WW 461 558 -17.4% -17.1% -0.3% 1,410 1,868 -24.5% -23.6% -0.9% SIMPONI / SIMPONI ARIA US 310 298 3.9% 3.9% - 866 886 -2.3% -2.3% - Intl 319 248 29.1% 30.2% -1.1% 829 797 4.1% 8.6% -4.5% WW 629 545 15.3% 15.8% -0.5% 1,695 1,682 0.8% 2.9% -2.1% STELARA US 1,912 1,655 15.5% 15.5% - 5,180 4,766 8.7% 8.7% - Intl 951 794 19.9% 16.2% 3.7% 2,925 2,571 13.8% 15.5% -1.7% WW 2,864 2,449 16.9% 15.8% 1.1% 8,105 7,336 10.5% 11.1% -0.6% TREMFYA US 634 530 19.6% 19.6% - 1,490 1,303 14.4% 14.4% - Intl 258 200 29.0% 26.3% 2.7% 747 613 21.9% 24.0% -2.1% WW 891 729 22.2% 21.5% 0.7% 2,237 1,916 16.8% 17.4% -0.6% OTHER IMMUNOLOGY US 2 5 -47.1% -47.1% - 9 14 -36.1% -36.1% - Intl 0 0 - - - 0 0 - - - WW 2 5 -47.1% -47.1% - 9 14 -36.1% -36.1% - INFECTIOUS DISEASES US 360 390 -7.8% -7.8% - 1,147 1,266 -9.4% -9.4% - Intl 500 905 -44.8% -50.7% 5.9% 2,420 2,642 -8.4% -9.3% 0.9% WW 859 1,295 -33.6% -37.8% 4.2% 3,566 3,908 -8.7% -9.3% 0.6% COVID-19 VACCINE US 0 0 - - - 0 120 * * - Intl 41 489 -91.5% -97.8% 6.3% 1,073 1,370 -21.6% -23.0% 1.4% WW 41 489 -91.5% -97.8% 6.3% 1,073 1,490 -27.9% -29.2% 1.3% EDURANT / rilpivirine US 9 9 10.2% 10.2% - 26 27 -0.5% -0.5% - Intl 287 237 21.4% 13.4% 8.0% 816 691 18.2% 16.4% 1.8% WW 297 245 21.0% 13.3% 7.7% 843 718 17.5% 15.8% 1.7% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 345 372 -7.3% -7.3% - 1,105 1,096 0.9% 0.9% - Intl 102 112 -9.5% -15.0% 5.5% 310 354 -12.5% -13.0% 0.5% WW 447 485 -7.8% -9.0% 1.2% 1,415 1,450 -2.4% -2.5% 0.1% OTHER INFECTIOUS DISEASES US 5 10 -42.7% -42.7% - 15 24 -35.5% -35.5% - Intl 69 68 2.0% 5.5% -3.5% 220 228 -3.4% 0.8% -4.2% WW 74 77 -3.6% -0.5% -3.1% 235 251 -6.4% -2.6% -3.8% % Change NINE MONTHS % Change -- 13 of 21 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency NEUROSCIENCE US 1,036 919 12.7% 12.7% - 3,043 2,658 14.5% 14.5% - Intl 706 763 -7.4% -5.1% -2.3% 2,296 2,498 -8.1% -4.2% -3.9% WW 1,742 1,681 3.6% 4.6% -1.0% 5,339 5,156 3.5% 5.4% -1.9% CONCERTA / Methylphenidate US 57 41 38.1% 38.1% - 191 114 67.4% 67.4% - Intl 133 117 13.6% 15.5% -1.9% 412 362 13.8% 19.0% -5.2% WW 189 158 20.0% 21.4% -1.4% 603 476 26.7% 30.7% -4.0% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 730 684 6.8% 6.8% - 2,164 2,036 6.3% 6.3% - Intl 299 348 -14.0% -14.4% 0.4% 940 1,097 -14.3% -11.9% -2.4% WW 1,029 1,031 -0.2% -0.3% 0.1% 3,104 3,132 -0.9% -0.1% -0.8% SPRAVATO US 154 88 75.1% 75.1% - 409 223 83.1% 83.1% - Intl 29 12 * * * 74 32 * * * WW 183 100 82.1% 81.0% 1.1% 483 255 88.8% 88.7% 0.1% OTHER NEUROSCIENCE US 94 106 -11.3% -11.3% - 278 285 -2.3% -2.3% - Intl 245 286 -13.9% -7.8% -6.1% 870 1,007 -13.5% -8.5% -5.0% WW 340 393 -13.2% -8.7% -4.5% 1,149 1,293 -11.0% -7.1% -3.9% ONCOLOGY US 2,219 1,812 22.5% 22.5% - 6,177 5,073 21.8% 21.8% - Intl 2,313 2,252 2.7% 0.7% 2.0% 6,865 6,983 -1.7% 0.3% -2.0% WW 4,533 4,064 11.5% 10.4% 1.1% 13,043 12,056 8.2% 9.3% -1.1% CARVYKTI US 140 55 * * - 324 79 * * - Intl 12 - * * - 17 - * * - WW 152 55 * * - 341 79 * * - DARZALEX US 1,369 1,097 24.8% 24.8% - 3,882 3,071 26.4% 26.4% - Intl 1,130 955 18.3% 16.0% 2.3% 3,312 2,823 17.3% 19.7% -2.4% WW 2,499 2,052 21.8% 20.7% 1.1% 7,194 5,894 22.1% 23.2% -1.1% ERLEADA US 288 254 12.9% 12.9% - 778 693 12.2% 12.2% - Intl 342 235 45.8% 42.3% 3.5% 961 647 48.7% 51.0% -2.3% WW 631 490 28.7% 27.0% 1.7% 1,740 1,340 29.8% 30.9% -1.1% IMBRUVICA US 264 353 -25.2% -25.2% - 796 1,072 -25.8% -25.8% - Intl 545 559 -2.5% -4.6% 2.1% 1,681 1,847 -9.0% -7.6% -1.4% WW 808 911 -11.3% -12.6% 1.3% 2,476 2,918 -15.2% -14.2% -1.0% ZYTIGA / abiraterone acetate US 16 16 -2.8% -2.8% - 41 54 -24.9% -24.9% - Intl 199 440 -54.9% -55.1% 0.2% 646 1,446 -55.3% -53.6% -1.7% WW 214 456 -53.0% -53.2% 0.2% 686 1,500 -54.2% -52.6% -1.6% OTHER ONCOLOGY US 143 37 * * - 357 104 * * - Intl 86 64 34.5% 30.4% 4.1% 248 220 12.5% 13.8% -1.3% WW 229 100 * * * 605 324 86.5% 87.4% -0.9% % Change NINE MONTHS % Change -- 14 of 21 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency PULMONARY HYPERTENSION US 680 604 12.6% 12.6% - 1,964 1,736 13.1% 13.1% - Intl 274 247 10.5% 11.7% -1.2% 835 810 3.0% 7.4% -4.4% WW 954 852 12.0% 12.4% -0.4% 2,798 2,547 9.9% 11.3% -1.4% OPSUMIT US 323 289 12.2% 12.2% - 924 827 11.8% 11.8% - Intl 166 152 9.3% 8.6% 0.7% 512 495 3.5% 6.8% -3.3% WW 490 441 11.2% 10.9% 0.3% 1,437 1,322 8.7% 9.9% -1.2% UPTRAVI US 336 283 18.9% 18.9% - 978 824 18.7% 18.7% - Intl 66 50 30.9% 33.8% -2.9% 185 162 14.1% 18.6% -4.5% WW 402 333 20.7% 21.1% -0.4% 1,163 986 18.0% 18.7% -0.7% OTHER PULMONARY HYPERTENSION US 20 33 -37.1% -37.1% - 61 86 -28.4% -28.4% - Intl 42 46 -7.5% -2.1% -5.4% 137 154 -10.5% -2.6% -7.9% WW 63 78 -19.8% -16.6% -3.2% 199 239 -16.9% -11.8% -5.1% CARDIOVASCULAR / METABOLISM / OTHER US 763 837 -8.8% -8.8% - 2,254 2,266 -0.5% -0.5% - Intl 194 198 -2.1% -4.7% 2.6% 580 651 -10.8% -9.8% -1.0% WW 957 1,034 -7.5% -8.0% 0.5% 2,834 2,916 -2.8% -2.6% -0.2% XARELTO US 625 689 -9.4% -9.4% - 1,840 1,806 1.9% 1.9% - Intl - - - - - - - - - - WW 625 689 -9.4% -9.4% - 1,840 1,806 1.9% 1.9% - OTHER US 139 147 -6.1% -6.1% - 414 459 -9.9% -9.9% - Intl 194 198 -2.1% -4.7% 2.6% 580 651 -10.8% -9.8% -1.0% WW 332 345 -3.8% -5.3% 1.5% 994 1,110 -10.5% -9.8% -0.7% TOTAL INNOVATIVE MEDICINE US 8,249 7,438 10.9% 10.9% - 23,090 21,229 8.8% 8.8% - Intl 5,644 5,776 -2.3% -4.3% 2.0% 17,947 18,171 -1.2% 0.8% -2.0% WW 13,893 $ 13,214 5.1% 4.3% 0.8% 41,037 $ 39,400 4.2% 5.1% -0.9% See footnotes at end of schedule % Change NINE MONTHS % Change -- 15 of 21 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER MEDTECH SEGMENT (2,3) 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 891 $ 547 63.0% 63.0% - 2,662 $ 1,566 70.0% 70.0% - Intl 667 513 29.9% 32.2% -2.3% 2,019 1,636 23.4% 28.6% -5.2% WW 1,558 1,060 47.0% 48.1% -1.1% 4,681 3,202 46.2% 48.9% -2.7% ELECTROPHYSIOLOGY US 611 520 17.6% 17.6% - 1,791 1,489 20.3% 20.3% - Intl 549 453 21.2% 23.4% -2.2% 1,658 1,454 14.0% 19.2% -5.2% WW 1,161 973 19.3% 20.3% -1.0% 3,449 2,943 17.2% 19.8% -2.6% ABIOMED US 254 - * * - 790 - * * - Intl 57 - * * - 176 - * * - WW 311 - * * - 966 - * * - OTHER INTERVENTIONAL SOLUTIONS US 26 27 -3.2% -3.2% - 81 77 5.9% 5.9% - Intl 61 60 1.0% 3.7% -2.7% 186 181 2.2% 7.2% -5.0% WW 87 87 -0.3% 1.6% -1.9% 267 258 3.3% 6.8% -3.5% ORTHOPAEDICS US 1,349 1,309 3.1% 3.1% - 4,100 3,936 4.2% 4.2% - Intl 815 785 3.9% 1.7% 2.2% 2,574 2,504 2.8% 4.9% -2.1% WW 2,164 2,095 3.4% 2.6% 0.8% 6,674 6,440 3.6% 4.5% -0.9% HIPS US 239 228 4.9% 4.9% - 730 693 5.4% 5.4% - Intl 136 124 9.3% 7.3% 2.0% 432 437 -1.0% 1.1% -2.1% WW 375 352 6.5% 5.8% 0.7% 1,162 1,129 2.9% 3.8% -0.9% KNEES US 207 203 2.3% 2.3% - 654 620 5.6% 5.6% - Intl 131 115 14.6% 11.7% 2.9% 415 386 7.7% 9.7% -2.0% WW 338 317 6.7% 5.7% 1.0% 1,069 1,005 6.4% 7.2% -0.8% TRAUMA US 488 473 3.2% 3.2% - 1,462 1,412 3.5% 3.5% - Intl 253 244 4.2% 0.8% 3.4% 775 749 3.5% 5.0% -1.5% WW 742 717 3.5% 2.4% 1.1% 2,238 2,161 3.5% 4.0% -0.5% SPINE, SPORTS & OTHER US 415 406 2.3% 2.3% - 1,254 1,211 3.5% 3.5% - Intl 295 303 -2.6% -3.6% 1.0% 952 933 2.0% 4.7% -2.7% WW 710 708 0.2% -0.2% 0.4% 2,205 2,144 2.8% 4.0% -1.2% % Change NINE MONTHS % Change -- 16 of 21 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency SURGERY US 994 984 1.1% 1.1% - 2,984 2,897 3.0% 3.0% - Intl 1,483 1,439 3.1% 4.6% -1.5% 4,522 4,410 2.6% 6.7% -4.1% WW 2,479 2,422 2.3% 3.2% -0.9% 7,507 7,306 2.7% 5.3% -2.6% ADVANCED US 455 457 -0.4% -0.4% - 1,365 1,328 2.8% 2.8% - Intl 709 701 1.0% 2.7% -1.7% 2,139 2,132 0.3% 4.5% -4.2% WW 1,164 1,158 0.5% 1.5% -1.0% 3,504 3,460 1.3% 3.8% -2.5% GENERAL US 540 527 2.4% 2.4% - 1,619 1,569 3.2% 3.2% - Intl 775 737 5.1% 6.5% -1.4% 2,383 2,277 4.7% 8.8% -4.1% WW 1,314 1,264 4.0% 4.8% -0.8% 4,002 3,846 4.1% 6.5% -2.4% VISION US 512 517 -1.0% -1.0% - 1,599 1,534 4.2% 4.2% - Intl 744 689 8.1% 10.1% -2.0% 2,265 2,170 4.4% 8.3% -3.9% WW 1,256 1,206 4.2% 5.4% -1.2% 3,864 3,704 4.3% 6.6% -2.3% CONTACT LENSES / OTHER US 399 405 -1.2% -1.2% - 1,252 1,179 6.2% 6.2% - Intl 529 503 4.9% 8.2% -3.3% 1,568 1,533 2.3% 7.0% -4.7% WW 928 908 2.2% 4.0% -1.8% 2,820 2,712 4.0% 6.6% -2.6% SURGICAL US 112 112 -0.1% -0.1% - 346 355 -2.5% -2.5% - Intl 216 186 16.6% 15.4% 1.2% 698 637 9.6% 11.7% -2.1% WW 328 298 10.3% 9.5% 0.8% 1,044 992 5.3% 6.6% -1.3% TOTAL MEDTECH US 3,747 3,356 11.6% 11.6% - 11,345 9,932 14.2% 14.2% - Intl 3,711 3,426 8.3% 9.2% -0.9% 11,382 10,719 6.2% 10.0% -3.8% WW 7,458 $ 6,782 10.0% 10.4% -0.4% 22,727 $ 20,651 10.0% 12.0% -2.0% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Previously referred to as Pharmaceutical (5) Reported as U.S. sales % Change Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change NINE MONTHS -- 17 of 21 -- 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Innovative Medicine U.S. 8,249 $ 7,438 10.9 % 10.9 - 23,090 $ 21,229 8.8 % 8.8 - International 5,644 5,776 (2.3) (4.3) 2.0 17,947 18,171 (1.2) 0.8 (2.0) Worldwide 13,893 13,214 5.1 4.3 0.8 41,037 39,400 4.2 5.1 (0.9) COVID-19 Vaccine U.S. - - - - - - 120 * * - International 41 489 (91.5) (97.8) 6.3 1,073 1,370 (21.6) (23.0) 1.4 Worldwide 41 489 (91.5) (97.8) 6.3 1,073 1,490 (27.9) (29.2) 1.3 Innovative Medicine excluding COVID-19 Vaccine U.S. 8,249 7,438 10.9 10.9 - 23,090 21,109 9.4 9.4 - International 5,603 5,287 5.9 4.3 1.6 16,874 16,801 0.4 2.7 (2.3) Worldwide 13,852 12,725 8.9 8.2 0.7 39,964 37,910 5.4 6.4 (1.0) Worldwide U.S. 11,996 10,794 11.1 11.1 - 34,435 31,161 10.5 10.5 - International 9,355 9,202 1.6 0.7 0.9 29,329 28,890 1.5 4.2 (2.7) Worldwide 21,351 19,996 6.8 6.4 0.4 63,764 60,051 6.2 7.5 (1.3) COVID-19 Vaccine U.S. - - - - - - 120 * * - International 41 489 (91.5) (97.8) 6.3 1,073 1,370 (21.6) (23.0) 1.4 Worldwide 41 489 (91.5) (97.8) 6.3 1,073 1,490 (27.9) (29.2) 1.3 Worldwide U.S. 11,996 10,794 11.1 11.1 - 34,435 31,041 10.9 10.9 - International 9,314 8,713 6.9 6.3 0.6 28,256 27,520 2.7 5.5 (2.8) Worldwide excluding COVID-19 Vaccine 21,310 $ 19,507 9.2 % 9.0 0.2 62,691 $ 58,561 7.1 % 8.4 (1.3) Note: Columns and rows within tables may not add due to rounding * Percentage greater than 100% or not meaningful Supplemental Sales Reconciliation (Unaudited) (Dollars in Millions) THIRD QUARTER NINE MONTHS Percent Change Percent Change -- 18 of 21 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2023 2022 2023 2022 2023 2022 2023 2022 Reported Income Before Tax by Segment From Continuing Operations $ 4,794 4,186 1,185 1,090 (762) (104) 5,217 5,172 % to Sales 34.5% 31.7% 15.9% 16.1% -3.6% -0.5% 24.4% 25.9% Intangible asset amortization expense 749 698 383 260 - - 1,132 958 In-process research and development impairments 206 - - - - - 206 - Litigation related (32) 7 (19) 212 - - (51) 219 Loss/(gain) on securities 398 177 (38) (13) 645 - 1,005 164 Restructuring related 149 23 235 69 - - 384 92 Acquisition, integration and divestiture related - - 22 - - - 22 - Medical Device Regulation - - 74 78 - - 74 78 COVID-19 Vaccine related costs 44 377 - - - - 44 377 Adjusted Income Before Tax by Segment From Continuing Operations $ 6,308 5,468 1,842 1,696 (117) (104) 8,033 7,060 % to Sales 45.4% 41.4% 24.7% 25.0% -0.5% -0.5% 37.6% 35.3% *Estimated as of 10/17/2023 Q3 QTD - Income Before Tax by Segment* Dollars in Millions Innovative Medicine MedTech Unallocated Worldwide Total -- 19 of 21 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2023 2022 2023 2022 2023 2022 2023 2022 Reported Income Before Tax by Segment From Continuing Operations $ 14,008 12,424 4,265 3,641 (8,037) (546) 10,236 15,519 % to Sales 34.1% 31.5% 18.8% 17.6% -12.6% -0.9% 16.1% 25.8% Intangible asset amortization expense 2,236 2,194 1,148 773 - - 3,384 2,967 In-process research and development impairments 206 610 49 - - - 255 610 Litigation related (125) 28 41 476 7,070 100 6,986 604 Loss/(gain) on securities 474 673 (43) 11 645 - 1,076 684 Restructuring related 424 32 235 221 - - 659 253 Acquisition, integration and divestiture related - - 102 - - - 102 - Medical Device Regulation - - 223 208 - - 223 208 COVID-19 Vaccine related costs 653 653 - - - - 653 653 Other - - - - - (7) - (7) Adjusted Income Before Tax by Segment From Continuing Operations $ 17,876 16,614 6,020 5,330 (322) (453) 23,574 21,491 % to Sales 43.6% 42.2% 26.5% 25.8% -0.5% -0.8% 37.0% 35.8% *Estimated as of 10/17/2023 Q3 YTD - Income Before Tax by Segment* Dollars in Millions Innovative Medicine MedTech Unallocated Worldwide Total -- 20 of 21 -- Third Quarter Oct. 1, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Third Quarter Oct. 1, 2023 Non-GAAP Cost of products sold 6,606 $ (1,132) (226) (34) (9) - - - 5,205 Selling, marketing and admin expenses 5,400 (6) 5,394 Research and development expense 3,447 - (33) (36) 3,378 Other (Income) / Expense 499 - 51 - (22) (1,005) - - - (477) In-process research and development impairments 206 (206) - Interest (Income)/Expense (182) (182) Restructuring 158 (158) - Provision for taxes on income 908 178 (12) 46 72 5 167 14 12 27 (161) - 1,256 Net Earnings from Continuing Operations 4,309 954 (39) 160 312 17 838 59 33 (27) 161 - 6,777 Third Quarter Oct. 2, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Third Quarter Oct. 2, 2022 Non-GAAP Cost of products sold 6,172 $ (958) (9) (29) (102) - - - 5,074 Selling, marketing and admin expenses 4,975 (7) 4,968 Research and development expense 3,485 - (42) (80) 3,363 Other (Income) / Expense 226 - (219) (18) - (164) (195) - - (370) In-process research and development impairments - - - Restructuring 65 (65) - Provision for taxes on income 862 146 (7) - 19 - 43 15 96 36 (88) - 1,122 Net Earnings from Continuing Operations 4,310 812 226 - 73 - 121 63 281 (36) 88 - 5,938 Nine Months Oct. 1, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Nine Months Oct. 1, 2023 Non-GAAP Cost of products sold 19,755 $ (3,380) (226) (91) (177) 15,881 Selling, marketing and admin expenses 15,702 (21) 15,681 Research and development expense 10,605 (16) (111) (98) 10,380 Other (Income) / Expense 7,055 (4) (6,986) - (86) (1,076) (378) - - (1,475) In-process research and development impairments 255 (255) - - - - Interest (Income)/Expense (277) (277) Restructuring 433 (433) - Provision for taxes on income 1,042 532 1,639 57 141 22 182 41 155 33 (117) - 3,727 Net Earnings from Continuing Operations 9,194 2,852 5,347 198 518 80 894 182 498 (33) 117 - 19,847 Nine Months Oct. 2, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Nine Months Oct. 2, 2022 Non-GAAP Cost of products sold 18,512 $ (2,967) (37) (76) (296) 15,136 Selling, marketing and admin expenses 14,907 (19) 14,888 Research and development expense 10,425 - (113) (190) 10,122 Other (Income) / Expense 15 - (604) (16) - (684) (167) - 7 (1,449) In-process research and development impairments 610 (610) - Restructuring 200 (200) - Provision for taxes on income 2,376 442 (89) 138 47 - 164 39 161 (62) (87) (2) 3,127 Net Earnings from Continuing Operations 13,143 2,525 693 472 206 - 520 169 492 62 87 (5) 18,364 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date Consumer Health separation tax related costs In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Tax legislation and other tax related Year to Date Consumer Health separation tax related costs In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs -- 21 of 21 --